About: Beloranib

An Entity of Type: person, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Beloranib is a former drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and its clinical development was led by Zafgen. Drug development was halted in 2016 after deaths during clinical trials.

Property Value
dbo:abstract
  • Beloranib is a former drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and its clinical development was led by Zafgen. Drug development was halted in 2016 after deaths during clinical trials. (en)
  • Beloranib é uma molécula em fase de testes que poderá tornar-se um medicamento contra a obesidade. Durante os testes em humanos a molécula fez mulheres perderem aproximadamente 1 kg por semana, sem a realização de exercícios físicos e efeitos colaterais significativos. Trata-se de um methionine aminopeptidase 2 inhibitor. É propriedade da farmacêutica dos Estados Unidos. (pt)
dbo:alternativeName
  • CKD-732; ZGN-433 (en)
dbo:iupacName
  • (3R,4S,5S,6R)-5-Methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl (2E)-3-{4-[2-(dimethylamino)ethoxy]phenyl}prop-2-enoate (en)
dbo:thumbnail
dbo:wikiPageID
  • 32539904 (xsd:integer)
dbo:wikiPageLength
  • 6674 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1095827705 (xsd:integer)
dbo:wikiPageWikiLink
dbp:imagefile
  • Beloranib.svg (en)
dbp:imagesize
  • 200 (xsd:integer)
dbp:othernames
  • CKD-732; ZGN-433 (en)
dbp:pin
  • -5 (xsd:integer)
dbp:verifiedfields
  • changed (en)
dbp:verifiedrevid
  • 461514628 (xsd:integer)
dbp:watchedfields
  • changed (en)
dbp:wikiPageUsesTemplate
dcterms:subject
gold:hypernym
rdf:type
rdfs:comment
  • Beloranib is a former drug candidate for the treatment of obesity. It was discovered by CKD Pharmaceuticals and its clinical development was led by Zafgen. Drug development was halted in 2016 after deaths during clinical trials. (en)
  • Beloranib é uma molécula em fase de testes que poderá tornar-se um medicamento contra a obesidade. Durante os testes em humanos a molécula fez mulheres perderem aproximadamente 1 kg por semana, sem a realização de exercícios físicos e efeitos colaterais significativos. Trata-se de um methionine aminopeptidase 2 inhibitor. É propriedade da farmacêutica dos Estados Unidos. (pt)
rdfs:label
  • Beloranib (en)
  • Beloranib (pt)
owl:sameAs
prov:wasDerivedFrom
foaf:depiction
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License